PPARA and diabetes mellitus: In addition to determining the direct effects of glucose on intestinal epithelial permeability, we also sought to determine if hyperglycemia-induced barrier dysfunction could be prevented with the PPARα agonist, fenofibrate, thus aiming to directly address the potential use of fenofibrate as a therapy for DM-related intestinal barrier dysfunction in feline veterinary patients while additionally supporting further investigation into the relationship between fenofibrate, diabetes, and intestinal barrier dysfunction in human patients.